Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Authors:
- 1 January 1992
- journal article
- clinical trial
- Published by Wiley in Movement Disorders
- Vol. 7 (3) , 239-243
Abstract
A selective dopamine D1‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1‐receptor stimulation may result in improvement of motor disability in PD.Keywords
This publication has 5 references indexed in Scilit:
- Blood pressure and plasma catecholamines in never‐treated parkinsonian patientsNeurology, 1990
- A double‐blind, placebo‐controlled, dose‐ranging study to investigate the safety and efficacy of CY 208‐243 in patients with Parkinson's diseaseNeurology, 1989
- Antiparkinsonian activity of CY 208–243, a partial D‐1 dopamine receptor agonist, in MPTP‐treated marmosets and patients with Parkinson's diseaseMovement Disorders, 1989
- Selective D-1 dopamine receptor agonist treatment of parkinson's diseaseJournal of Neural Transmission, 1987
- The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmosetNeuroscience Letters, 1985